← All candidates
49 insider filings on record.
Gilbert Ray Cisneros, Jr.Small Business · Armed Servicestraded 7 Aug · filed 10 Sep · selfBought$1K–$15Kself7 Aug41d ago10 Sep7d ago49 filings on record.
NEONEOGENOMICS INC
NasdaqCM · Healthcare · $2.43B
$18.94
+0.26% · Sep 16
49 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 3 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$2.43B
Float
117.0M
91% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
56.0
Price / sales
3.2
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Chief Financial Officer
Sherman Jeffrey Scott
Bought $112.3K on Aug 6 — 20,000 sh @ $5.62, held direct, 11% of their stake.
1 of 1 position beat the S&P
Chief Executive Officer
Zook Anthony P.
Bought $100.0K on Aug 6 — 17,900 sh @ $5.58, held direct, 47% of their stake.
1 of 1 position beat the S&P
Director
Kelly Michael Aaron
Bought $38.0K on May 27 — 5,000 sh @ $7.60, held indirect, 100% of their stake.
1 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
Congress
▸ Disclosures lag trades by 30–45 days.
1 disclosure12 mo
MemberTradeAmountOwnerTradedFiled
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
44 more transactions on Pro →Context
Wall St
$15.11 avg target
-20.2% vs today · 9 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
4 of 4 quarters beat
Q1 '26$0.01 act+$0.01
Q4 '25$0.06 act+$0.02
Q3 '25$0.03 act+$0.01
Q2 '25$0.03 act+$0.01
Coverage
A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The PackStockStory · 06-26NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?Zacks · 06-19Is NeoGenomics (NEO) Using Its ASCO ctDNA Focus To Redefine Its Precision Oncology Edge?Simply Wall St. · 05-27NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To KnowStockStory · 05-17
The file stays open
49 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice